Palisade Bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $366.0M
- Price
- $2.10
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.94%
- Volume
- 1.1M
About
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.
Quick stats
Shares outstanding174.3M
Computed float165.0M
Float / shares94.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001357459
Websitehttps://www.palisadebio.com
AI Summary
AI-generated1/17
standardbullishearnings
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
Palisade Bio reported a Q2 net loss of $10.6 million, or $0.05 per share, driven by increased R&D and G&A expenses as the company prepares for Phase 2 trials. The company ended the quarter with $125.2 million in cash, which management believes is sufficient to fund operations through key clinical readouts expected in 2027 and 2028.
The company is advancing PALI-2108 into Phase 2 development for ulcerative colitis and Crohn's disease, with the ASCENTRA-UC trial expected to commence in the second half of 2026. Phase 1 data demonstrated favorable safety and tolerability, with 5 out of 5 UC patients achieving clinical response.
Palisade strengthened its board with the appointment of biopharmaceutical veterans Robert Baltera and Jordan Zwick to support the clinical advancement of PALI-2108.
Red flags
- Net loss increased from $2.8M to $10.6M year-over-year
- R&D expenses increased significantly to $7.4M from $1.7M due to stock-based compensation and clinical ops